Multibiotic Agents via Hydrolyzable Linkers for Targeted Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for modulating the mammalian microbiota primarily focus on probiotics, with small molecules leveraging bidirectional communication between the host and microbiota remaining underutilized for pharmaceutical and nutraceutical applications.
Innovation Solution
Development of multibiotic agents comprising compounds with alcohol cores, amine cores, and acyls covalently linked through hydrolyzable bonds like ester, amide, azo, glycosidic, carbonate, or carbamate linkers, which are designed to be activated by human microbiota and administered to target specific health conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used to leverage bidirectional communication between host and microbiota, then treatment efficacy and specificity are improved, but utilization for pharmaceutical and nutraceutical applications remains underdeveloped
Solution Approach 1:
The patent creates multibiotic agents that can function across multiple pharmaceutical and nutraceutical applications by combining different bioactive compounds (probiotics, prebiotics, postbiotics, and small molecules) into a single compositional framework that addresses various health conditions including cardiovascular disease, diabetes, and inflammatory bowel disease
Solution Approach 2:
The invention develops composite multibiotic formulations that integrate multiple types of bioactive compounds (live microorganisms, metabolic byproducts, and small molecule therapeutics) working synergistically to enhance treatment efficacy while expanding applicability across different disease states
2Reliability
If probiotics are used as active agents, then microbiota modulation is achieved, but small molecule-based approaches remain underutilized
Solution Approach 1:
The patent merges probiotics, prebiotics, postbiotics, and small molecule therapeutics into integrated multibiotic formulations, combining the proven microbiota-modulating effects of live microorganisms with the pharmacological advantages of small molecules to achieve enhanced therapeutic outcomes
3Measurement precision
If multibiotic agents deliver biologically active compounds to target sites, then treatment specificity is improved, but complexity of the compositional framework increases
Solution Approach 1:
The patent segments the delivery system into distinct functional components (probiotics for colonization, prebiotics for substrate provision, postbiotics for immediate effect, and small molecules for targeted pharmacology) that can be independently optimized and combined based on specific therapeutic needs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These multibiotic agents effectively modulate various health markers, such as cardiovascular, diabetes, inflammatory bowel disease, and other conditions by delivering biologically active compounds to target sites within the body, enhancing treatment efficacy and specificity.
Implementation Method 1
multibiotic agents comprising compounds with alcohol cores, amine cores, and acyls covalently linked through hydrolyzable bonds like ester, amide, azo, glycosidic, carbonate, or carbamate linkers, which are designed to be activated by human microbiota
Data Source
Figure 1
AI summary
Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.